We, therefore, decided to conduct a prospective trial evaluating the potential role of early pharmacological intervention with ACEis and BB in patients with operable, HER2 positive breast cancer who, during trastuzumab treatment, developed LVEF loss not requiring trastuzumab discontinuation. Here, ERBB2 is linked to breast cancer.